Why Is DENTSPLY SIRONA INC (XRAY) Stock Down Today?

Why XRAY stock is down today

XRAY stock fell 7.97% to $12.12 in the session, driven by disappointing second-quarter results and mixed guidance from DENTSPLY SIRONA. The company reported Q2 2026 revenue of $898 million, a 4.1% decline on a reported basis and 6.3% on a constant-currency basis. The earnings call highlighted ongoing challenges in the company’s turnaround plan, raising concerns among investors.

What Happened

DENTSPLY SIRONA’s second-quarter performance fell short of expectations despite beating revenue and adjusted earnings estimates in the quarter. The company affirmed its full-year 2026 adjusted EPS guidance of $1.40 to $1.50 and sales guidance of $3.5 billion to $3.6 billion, but the reported revenue decline and ongoing unprofitability weighed on sentiment. The stock’s sharp decline came amid a broader backdrop of cautious investor sentiment toward the dental products sector.

Three recent analyst actions included BMO Capital initiating coverage with a Market Perform rating and a $12 price target, and Piper Sandler raising its price target to $14 while maintaining a Neutral stance. DENTSPLY SIRONA also announced an expanded partnership with Medline Sinclair to distribute its technology portfolio in Canada, effective September 1.

What The Data Shows

XRAY has a market cap of $2.6 billion and remains unprofitable, with a trailing twelve-month EPS of -2.73 and a net margin of -15.0%. Revenue has declined 0.8% over the trailing twelve months. The stock is currently trading within its 52-week range of $9.40 to $14.86. Recent insider activity shows six buys totaling $617,000 by directors in the last 90 days, with the most recent purchase on June 18.

What To Watch

The stock is currently trading below its 52-week average and faces pressure from its unprofitable fundamentals. Investors should monitor the company’s progress in its turnaround plan and any further analyst updates or corporate actions.